



(51) International Patent Classification:

C07D 401/04 (2006.01) C07D 491/04 (2006.01)
 C07D 401/14 (2006.01) C07D 495/04 (2006.01)
 C07D 471/04 (2006.01) C07D 498/04 (2006.01)
 C07D 487/04 (2006.01) A61K 31/4523 (2006.01)
 C07D 513/04 (2006.01) A61K 35/00 (2006.01)

(21) International Application Number:

PCT/IB2012/053613

(22) International Filing Date:

13 July 2012 (13.07.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/507,321 13 July 2011 (13.07.2011) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEN, Christine Hiu-Tung** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts US (US). **CHIN, Noel Chin** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **DIPIETRO, Lucian V.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **FAN, Jianme** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **PALERMO, Mark G** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Mas-

sachusetts Avenue, Cambridge, MA 02139 (US). **SHULTZ, Michael David** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts, Cambridge, Massachusetts 02139 (US). **TOURE, Bakary-Barry** [CA/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).

(74) Agents: **STRANG, Andrea** et al.; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS



(57) Abstract: The present invention provides for compounds of formula (I). The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.